Dosing tacrolimus based on CYP3A5 genotype: Will it improve clinical outcome?
Tacrolimus, widely used to prevent acute rejection following solid-organ transplantation, has become the cornerstone of immunosuppressive therapy after kidney transplantation. More than 70% of all renal transplant recipients receive this remarkably effective agent. 1 But tacrolimus is also highly toxic, and there is great between-patient variability in its pharmacokinetics. This, combined with a low therapeutic index, mandates routine therapeutic drug monitoring in clinical practice. 2 Typically, predose concentrations are monitored and the dose is adjusted to aim for target values that depend on immunological risk, comedication, and time since transplantation.
|Persistent URL||dx.doi.org/10.1038/clpt.2010.42, hdl.handle.net/1765/27433|
|Journal||Clinical Pharmacology and Therapeutics|
van Gelder, T, & Hesselink, D.A. (2010). Dosing tacrolimus based on CYP3A5 genotype: Will it improve clinical outcome?. Clinical Pharmacology and Therapeutics, 87(6), 640–641. doi:10.1038/clpt.2010.42